Meropenem CAS 96036-03-2

Product Description:

Product Name: Meropenem CAS NO: 96036-03-2

Synonyms:

MEROPENEM, ANTIBIOTIC FOR CULTURE MEDIA USE ONLY;

(1'R,3'S,5'S,4R,5S,6S)-3-(5-DIMETHYLCARBAMOYL-PYRROLIDIN-3-YLSULFANYL)-6-(1-HYDROXY-ETHYL)-4-METHYL-7-OXO-1-AZA-BICYCLO[3.2.0]HEPT-2-ENE-2-CARBOXYLIC ACID;

MEROPENEM (PATENTED);

Chemical & Physical Properties:

Appearance: White or almost white powder Complies

Assay :≥99.00%

Density: 1.42 g/cm3

Boiling Point: 627.4℃ at 760 mmHg

Flash Point: 333.2℃

Refractive Index: 1.639

Safety Information:

Safety Statements: S26-37/39

HS Code: 2933990090

Risk Statements: R36/37/38

Hazard Code: Xi

Meropenem is a carbapenem antibiotic, which displaying a broad spectrum of antibacterial activity.Target: AntibacterialMeropenem, a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. Ceftriaxone and c-iprofloxacin demonstrated activity superior to that of both carbapenems while the activity of ceftazidime was similar to that of meropenem [1]. Meropenem, like imipenem and various experimental penems, may overcome the resistance problems presented by Class I beta-lactamases [2]. MEROPENEM was rapidly penetrated to the pleural effusion and was retained for a more prolonged time in the pleural effusion than in the blood of patients with accumulated pleural effusion, and it suggested the usefulness of MEROPENEM in antibacterial therapy for patients with pleurisy causing accumulation of pleural effusion [3].Clinical indications: Appendicitis; Bacterial infection; Bacterial meningitis; Bacterial pneumonia; Bacterial respiratory tract infection; Bacterial skin infection; Bacterial urinary tract infection; Bacteroides fragilis infection; Bacteroides infection; Bacteroides thetaiotaomicron infection; Complicated skin and skin structure infectionFDA Approved Date: July 1996Toxicity: In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.

If you are interested in our products or have any questions, please feel free to contact us!

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.